



iKnowMed May 2026 Release Preview



iKnowMed May 2026 | Release Highlights



Smarter Order Management



New Therapeutic Interchange Management (TIC) automatically applies your practice's preferred drug selections and payer-specific rules at the point of order entry, reducing denials and rework.

The Apply Special Schedule button now enforces required NDC and Waste fields before an order can be placed, preventing incomplete billing data from slipping through.

Faster Practice Administration



Roll out the redesigned order entry experience for all active users with the Non-Medication Orders permission set to Full in one step.

Enable automatic insurance plan name syncing from your PMS to keep patient data consistent without manual effort.

Therapeutic Interchange Management

Designed to reduce downstream corrections and delays, while preserving clinician control



What's Changing

Therapeutic Interchange Management (TIC) helps practices align therapy selection with payer and practice preferences during new regimen ordering, so teams can avoid preventable rework later in the workflow.



Why TIC Matters

- Payer preferences and therapeutic alternatives continue to expand
- Misaligned selection at order entry require manual edits to prevent delays and denials
- Downstream updates create avoidable burden across clinical, pharmacy, and revenue cycle teams



What to Expect

- Applies to new patient regimen orders only (not active patient regimens)
- Rollout and configuration are practice-controlled through permissions and effective dates

TIC & Your Practice



Guidance at the point of ordering

Practice or payer-aligned options are presented during new regimen order entry to reduce downstream corrections



Built-in transparency

TIC icon shows why a selection was applied: payer rule vs practice preference, with details in the Orders Queue + Insurance Auth/Financial Counseling queues.



Clinical control is preserved

Providers can override when clinically appropriate, with rationale captured for downstream visibility.

Therapeutic Interchange Management

>



Dawson Blue (69 / F)



DOB: 04/02/1957 MRN: PI-89737ZHDU Attending: - Dx: - Ht/Wt/BSA: 68 in / 122 lb / 1.63 m2 Allergies: Undefined

 Chart Summary

 Clinical Profile

 Flowsheet

 Orders

 Results

 Documents

 Demographics

 Nursing Care

 Scheduler

 Admix

 Charge Capture

 Messages

 USP





New Orders (0)

Medications (0)

Regimens (18)

Order Review

Order History

Drafts

PRECISION MEDICINE

ALERTS

 Filgrastim D1-5 Q7D

ADD TREATMENT GROUP

MEDICATIONS	Add an Order	Search Orderables	Dose	Calculated Dose	Schedule	
☐ Nivestym (Filgrastim-aafi Subcutaneous) Nivestym (Filgrastim-aafi Subcutaneous) 300 mcg/0.5 mL syringe 300 mcg subcutaneously once. Instructions: NOTE: This is Nivestym.			300 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Nivestym (Filgrastim-aafi Subcutaneous) Nivestym (Filgrastim-aafi Subcutaneous) 480 mcg/0.8 mL syringe 480 mcg subcutaneously once. Instructions: NOTE: This is Nivestym.			480 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Nivestym (Filgrastim-aafi Subcutaneous) 277 mcg (5 mcg/kg; Weight: 55.34 kg = 277 mcg) Nivestym (Filgrastim-aafi Subcutaneous) 480 mcg/0.8 mL syringe 277 mcg subcutaneously once. Instructions: NOTE: This is Nivestym.			5 mcg/kg	277 mcg	C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Releuko (Filgrastim-ayow Subcutaneous) Releuko (Filgrastim-ayow Subcutaneous) 480 mcg/0.8 mL syringe 480 mcg subcutaneously once. Instructions: NOTE: This is Releuko.			480 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Releuko (Filgrastim-ayow Subcutaneous) 277 mcg (5 mcg/kg; Weight: 55.34 kg = 277 mcg) Releuko (Filgrastim-ayow Subcutaneous) 480 mcg/0.8 mL syringe 277 mcg subcutaneously once. Instructions: NOTE: This is Releuko.			5 mcg/kg	277 mcg	C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Zarxio (Filgrastim-Sndz Subcutaneous) Zarxio (Filgrastim-Sndz Subcutaneous) 300 mcg/0.5 mL syringe 300 mcg subcutaneously once. Instructions: NOTE: This is Zarxio.			300 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Zarxio (Filgrastim-Sndz Subcutaneous) Zarxio (Filgrastim-Sndz Subcutaneous) 480 mcg/0.8 mL syringe 480 mcg subcutaneously once. Instructions: NOTE: This is Zarxio.			480 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Releuko (Filgrastim-ayow Subcutaneous) Releuko (Filgrastim-ayow Subcutaneous) 300 mcg/0.5 mL syringe 300 mcg subcutaneously once. Instructions: NOTE: This is Releuko.			300 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☒ Nypozi (filgrastim-txid Subcutaneous) Nypozi (filgrastim-txid Subcutaneous) 300 mcg/0.5 mL syringe			300 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
Insurer-based rule for Patient's Primary Insurance (UNITED HEALTHCARE / PO BOX 30555) 277 mcg subcutaneously once. Instructions: NOTE: This is Zarxio.			5 mcg/kg	277 mcg	C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Nypozi (filgrastim-txid Subcutaneous) Nypozi (filgrastim-txid Subcutaneous) 480 mcg/0.8 mL syringe 480 mcg subcutaneously once. Instructions: NOTE: This is Nypozi.			480 mcg		C1D1,C1D2,C1D3,C1D4,C1D5	X
☐ Nypozi (filgrastim-txid Subcutaneous) 277 mcg (5 mcg/kg; Weight: 55.34 kg = 277 mcg) Nypozi (filgrastim-txid Subcutaneous) 480 mcg/0.8 mL syringe 277 mcg subcutaneously once. Instructions: NOTE: This is Nypozi.			5 mcg/kg	277 mcg	C1D1,C1D2,C1D3,C1D4,C1D5	X
Neupogen (Filgrastim Subcutaneous)						

Therapeutic Interchange Management

Dawson Blue (69 / F)

DOB: 04/02/1957

MRN: PI-89737ZHDU

Attending: -

Dx: -

Ht/Wt/BSA: 68 in / 122 lb / 1.63 m2

Allergies: Undefined

Chart Summary

Clinical Profile

Flowsheet

Orders

Results

Documents

Demographics

Nursing Care

Scheduler

Admix

Charge Capture

Messages

USP

DECISION TOOLS

New Orders (0)

Medications (0)

Regimens (18)

Order Review

Order History

Drafts

PRECISION MEDICINE

ALERTS

Filgrastim D1-5 Q7D

ADD TREATMENT GROUP

Outbound Fax Ins. Auth/Fin. Counseling Oncology Case Model OCM Patient List **Orders Queue** Orders I/F Transcription Scheduler Unified Sign Queue

Blue, Dawson (F)
PI-89737ZHDU
04/02/1957 (69 yo)
Patient Notes:
68 in, 122 lb, 1.63 m2 (04/22/2026)

[MESSAGE](#)

Phone: [icon]
Address: 59239 Castillo Fort, Rew, PA, 16744
Email: JxMEeYO93@gmail.com
Problem(s): [icon]
Insurance: UNITED HEALTHCARE / PO BO...
Attending:
Allergies: NKA
Next MD Visit:

< PREVIOUS
NEXT >
☐ Select All Orders
 ☐ Select Labs

Update Selected Orders:

Location Type	Perform Location	Perform Date	Queue Task	Update Status	Queue Note
Select Option	Select Option	MM/DD/YYYY	Select O	Select Option	Add Note

☐ Use My Logged-in Location

[SAVE](#)

Wednesday, April 22, 2026

Nypozi
Filgrastim D1-5 Q7D (MEDICATIONS) [icon]

Insurer-based rule for Patient's Primary Insurance (UNITED HEALTHCARE / PO BOX 30555)
Reason: Value-Based Program

PHARMACY REVIEW: COMPLETE

Dose Form: 300 mcg/0.5 mL syringe
Sig: 300 mcg subcutaneously once. Instructions: NOTE: This is Nypozi.
Associated Problem: Neutropenia
Ordered/Edited By: Jones, Doctor on 04/22/2026
[Add chart comments](#)

Group By [Order Date \(Oldest to Newest\)](#)

☐ Show all from past 13 months

Wednesday, April 22, 2026

Blue, Dawson (F)
PI-89737ZHDU
04/02/1957 (69 yo)
Patient Notes:
68 in, 122 lb, 1.63 m2 (04/22/2026)

Nypozi
Filgrastim D1-5 Q7D (MEDICATIONS) [icon]

Insurer-based rule for Patient's Primary Insurance (UNITED HEALTHCARE / PO BOX 30555)
Reason: Value-Based Program

PHARMACY REVIEW: COMPLETE

Dose Form: 300 mcg/0.5 mL syringe
Sig: 300 mcg subcutaneously once. Instructions: NOTE: This is Nypozi.
Associated Problem: Neutropenia
Ordered/Edited By: Jones, Doctor on 04/22/2026
[Add chart comments](#)

Group By [Order Date \(Oldest to Newest\)](#)

☐ Show all from past 13 months

Wednesday, April 22, 2026

Next MD Visit:	Dose Form: 300 mcg/0.5 mL syringe Sig: 300 mcg subcutaneously once. Instructions: NOTE: This is Nypozi.	Regimen cycles (▼) Tx Days Type: N Location
Group By Order Date (Oldest to Newest) ▼	Associated Problem: Neutropenia Ordered/Edited By: Jones, Doctor on 04/22/2026 Add chart comments	Outbound Fax Ins. Auth/Fin. Counseling
☐ Show all from past 13 months Wednesday, April 22, 2026		✓  Blue, Dawson (F) PI-89737ZH DU 04/02/1957 (69 yo) Patient Notes: 68 in, 122 lb, 1.63 m2 (04/22/2026) MESSAGE  Phone:  Address: 59239 Castillo Fort, Rew, PA, 16744 Email: JxMEeYO93@gmail.com Problem(s):  Insurance: UNITED HEALTHCARE / PO BO...  Attending: Allergies: NKA Next MD Visit:
		Group By Order Date (Oldest to Newest) ▼
		☐ Show all from past 13 months Thursday, April 23, 2026
		Zarxio (Filgrastim-Sndz Subcutaneous)

Therapeutic Interchange Management

Documents

Outbound Fax

Ins. Auth/Fin. Counseling

Oncology Care Model

OCM Patient List

Orders Queue

Orders I/F

Tr:

...

Blue, Dawson (F/69 - 04/02/1957 - PI-89737ZHDU)

CoverMyMeds + ADD ALERT AUDIT HISTORY

Regimen: Filgrastim D1-5 Q7D

Number of Cycles: 1

Prim. Ins.: UNITED HEALTHCARE / PO BOX 30555

Sec. Ins.: AETNA LIFE INSURANCE CO / PO BOX 981106

Diagnosis/Problem: Neutropenia

ICD10: Not Documented

LOT: Toxicity Management

Cycle Length: 7

Planned Start Date: 04/22/2026

Insurance Start Date: 01/01/2020

Planned End Date:

Insurance End Date:

Date of Dx:

Stage: Not Documented

Business Office Status:

Obtained: 1 (C1)

Not Obtained: 0

Select Authorization:

▼

Pending

Obtained

Not obtained

Off label

Not needed

Declined

Status: Obtained

Insurance: UNITED HEALTHCARE / PO BOX 30555 (Primary)

Date Range

Start Date: 04/22/2026

End Date:

Authorization #: 1222

Cycles: 1

Reference #:

Contact:

Current Payer Decision

No decision from Payer yet.

Notes:

Initial Regimen Orders

Medications

TIC

Nypozi (filgrastim-txid Subcutaneous)

Nypozi (filgrastim-txid Subcutaneous) 300 mcg/0.5 mL syringe

Insurer-based rule for Patient's Primary Insurance (UNITED HEALTHCARE / PO BOX 30555)

Reason: Value-Based Program

Documents

Outbound Fax

Ins. Auth/Fin. Counseling

Oncology Care Model

OCM Patient List

Orders Queue

Orders I/F

Tr:

...

Blue, Dawson (F/69 - 04/02/1957 - PI-89737ZHDU)

CoverMyMeds + ADD ALERT AUDIT HISTORY

Regimen: Filgrastim D1-5 Q7D

Number of Cycles: 1

Prim. Ins.: UNITED HEALTHCARE / PO BOX 30555

Sec. Ins.: AETNA LIFE INSURANCE CO / PO BOX 981106

Diagnosis/Problem: Neutropenia

ICD10: Not Documented

LOT: Toxicity Management

Cycle Length: 7

Planned Start Date: 04/22/2026

Insurance Start Date: 01/01/2020

Planned End Date:

Insurance End Date:

Date of Dx:

Stage: Not Documented

Business Office Status:

Obtained: 0

Not Obtained: 1 (C1)

Select Authorization: New Authorization

▼

Pending

Obtained

Not obtained

Off label

Not needed

Declined

Status: Not obtained

Insurance: Select

Reference #:

Contact:

Current Payer Decision

No decision from Payer yet.

Notes:

Initial Regimen Orders

Medications

OTIC

Zarxio (Filgrastim-Sndz Subcutaneous)

Zarxio (Filgrastim-Sndz Subcutaneous) 480 mcg/0.8 mL syringe

Insurer-based rule for Patient's Primary Insurance (UNITED HEALTHCARE / PO BOX 30555)

Override by: Doctor Jones MD on 04/23/2026

Reason: Patient Preference

New Orders Redesign: Enable for users with Non-Medication Orders permission at once

May 2026 Release

What's Changing?

Practice administrators can now activate the New Orders Redesign for all active users with the Non-Medication Orders permission set to Full in their practice simultaneously, rather than enabling it one user at a time.

Why?

This removes the burden of configuring the New Orders Redesign user by user, making practice-wide rollout faster and more consistent so your team can take full advantage of the redesigned experience without delay.

Admixture: NDC and Waste hard stop extended to Apply Special Schedule button

May 2026 Release

What's Changing?

- The Apply Special Schedule button in the Admix Planning queue will now be grayed out — just like the Save button — until the required NDC and Waste fields are completed.
- Previously, the Save button was correctly blocked, but users could bypass the requirement by clicking Apply Special Schedule and placing the order without the necessary billing information.

Why?

- Ensuring NDC and Waste information is captured before an order is placed regardless of how it is saved helps practices avoid incomplete billing data and reduces downstream charge errors.

NDC and Waste hard stop extended to Apply Special Schedule button

Admix Planning

Treatment Status: All

From: 04/21/2026 To:

Date	Status
04/27/2026	Unplanned
05/04/2026	Unplanned
05/11/2026	Unplanned
05/18/2026	Unplanned
06/08/2026	Unplanned
06/15/2026	Unplanned
06/22/2026	Unplanned
06/29/2026	Unplanned
07/06/2026	Unplanned
07/13/2026	Unplanned
08/03/2026	Unplanned
08/10/2026	Unplanned
08/17/2026	Unplanned
08/24/2026	Unplanned

Planning for 04/27/2026

SAVE APPLY SPECIAL SCHEDULE REVERT TO DEFAULT PLAN MARK ALL AS PLANNED PRINT LABEL... DOUBLE CHECK...

Regimen Display Name	Cycle/Day	Business Office Approval	Clinical Approval	Description
Docetaxel D1,8,15,22,29,36 Q56D (Breast)	C1D15	Not obtained	Business Office Approval Required	

Famotidine IV10 mg/mL solution

Planned Skip Double Check Print Label

ACTIONS Famotidine IV10 mg/mL solution 20 mg, intravenously Insurance PRN Dispense Data

NDC (NDC needed for billing) Dose Form Description Amount UOM Amount in mL Waste (Waste needed for billing)

--Select NDC-- 10 mg/mL solution 20 mg mL mg Add another NDC

Admix Fluid Select an Admixture Fluid Admix Fluid Volume mL Total Volume mL Administer Over Select Enter Bag Data

Hydrocortisone IV

Planned Skip Double Check Print Label

ACTIONS Hydrocortisone IV 100 mg, intravenously Insurance PRN Dispense Data

NDC Dose Form Description Amount UOM Amount in mL Waste

--Select NDC-- --Select Dose Form-- 100 mg mL mg Add another NDC

Admix Fluid Select an Admixture Fluid Admix Fluid Volume mL Total Volume mL Administer Over Select Enter Bag Data

Texas Practices: 72-Hour hold on test results for SB 922 compliance

May 2026 Release

What's Changing?

- SB 922 requires physicians to delay electronic release of certain “sensitive test results” by three days (72 hours) after finalization. This applies to pathology or radiology reports with a reasonable likelihood of malignancy, or genetic marker tests.
- Labs, imaging, and other applicable results will be withheld from the Ontada Health portal until 72 hours have passed or the provider signs off on the result before that window closes.

Why?

- This update keeps Texas practices in compliance with state law regarding the disclosure of sensitive health information, while preserving provider control over when results are shared with patients.

Orders: PDMP availability for multi-practice providers

May 2026 Release

What's Changing?

- Providers who work across multiple practices will now see PDMP availability based on the practice they are currently signed into.
- When logged into a PDMP-enabled practice, the functionality will be available. When the active practice is not PDMP-enabled, PDMP will not be shown. There is no change for single-practice providers.

Why?

- For providers who work across multiple practices, PDMP access is now more predictable and consistent. Aligning PDMP availability with the currently active practice helps ensure providers see the right information at the right time, supporting compliance with state PDMP requirements.

Demographics: Insurance Plan Name syncs from PMS

May 2026 Release

What's Changing?

- iKnowMed can now update a patient's insurance Plan Name in Demographics > Insurance automatically based on information from your practice management system (PMS), keeping insurance data consistent across both systems.

Why?

- Manually maintaining insurance plan names across systems is time-consuming and prone to discrepancies. This integration helps ensure patient insurance information stays accurate and up to date without additional manual effort.

Demographics: Insurance Plan Name syncs from PMS

Edit Insurance required

Note : Choose a new file to upload. If you don't choose a new file it will preserve the existing file.

Document Type : --Please Select--

Type : Primary

Insurer's Name : AETNA

Policy Number :

Insured Name : test insuranceauth

Member ID :

Subscriber Name :

Subscriber ID :

Patient Relationship to Subscriber : Self

Effective Date :

Expiration Date :

Medicare Part A? ☐ Yes ☐ No ☒ Unknown

Medicare Part B? ☐ Yes ☐ No ☒ Unknown

File Uploaded :

Group Name :

Group ID :

Plan Name : Aetna PPO

Plan ID :

Select a File : Choose File No file chosen

Comments :

SAVE CANCEL

Mobile: Regimen Treatment Day Approval

May 2026 Release




What's Changing?

- New Feature in the iKnowMed Mobile App allows providers to approve and unapprove a patient's regimen treatment day via the mobile regimen card

Why?

- Allows providers to sign off on a patient's treatment while they are away from their office to improve provider's efficiency and prevent disruption to clinic workflow

Mobile: Regimen Treatment Day Approval



Additional Updates

Item	Overview
Fix: MAR accurately reflects Lynx dispense activity	Dispense, return, and re-dispense actions performed in Lynx will now consistently and accurately update the iKnowMed Medication Administration Record (MAR). Previously, some pharmacy actions were not reflected in the MAR at all, only partially updated, or displayed outdated dispense data.
Fix: Molecular Results in iKnowMed	Our team has made an update to refine how molecular results are delivered to iKnowMed Generation 2. In very rare instances historical results may display as a new result with the original date of service.



WE WANT TO HEAR FROM YOU

Share your feedback on the latest
iKnowMed release

Thursday, May 7, 2026,
at noon CT
during Office Hours

[Sign Up For Office Hours](#)